The synthetic flavonoids EMD 23188 and EMD 49209, developed as T 4 analogs, displace T 4 from transthyretin, and in vitro they inhibit 5Ј-deiodinase activity. In vivo EMD 21388 causes tissue-specific changes in thyroid hormone metabolism. In tissues that are dependent on T 3 locally produced from T 4 , total T 3 was diminished. It was not known whether it was the presence of EMD interfering with 5Ј-deiodinase type II in tissues or the decreased T 4 (substrate) availability that caused the lowered T 3 . To study whether the flavonoids enter tissues and, if this were the case, whether they enter tissues similarly, F LAVONOIDS, naturally occurring secondary metabolites and dyes in plants, have been shown to be the main constituents of folk remedies used for the treatment of thyroid and other hormonal disorders (1-4). Early studies indicated that natural flavonoids are able to induce goiter. Together with an increase in thyroid weight, a reduced iodide organification was found (5). Recently, it has been shown that flavonoids as constituents in a staple food, the African millet, are the cause of goiter and associated disorders (6). To study the interactions of flavonoids with the iodine-thyroid hormone system, a model was chosen in the form of synthetic flavonoids. These flavonoids were developed by means of molecular drug design (1, 2, 4). The synthetic flavonoids 3-methyl-4Ј,6-dihydroxy 3Ј,5Ј-dibromo-flavone (EMD 21388) and 3-methyl-4Ј,6-dihydroxy 3Ј,5Ј-diiodo-flavone (EMD 49209), both T 4 analogs, are potent inhibitors of the binding of T 4 to transthyretin (TTR), but not to other plasma proteins (1, 2, 7, 8). These specific TTR competitors are useful tools to study distribution and kinetics of T 4 , as the synthetic flavonoids redistribute endogenous T 4 without the need to add exogenous (pharmacological) T 4 .
F LAVONOIDS, naturally occurring secondary metabolites and dyes in plants, have been shown to be the main constituents of folk remedies used for the treatment of thyroid and other hormonal disorders (1) (2) (3) (4) . Early studies indicated that natural flavonoids are able to induce goiter. Together with an increase in thyroid weight, a reduced iodide organification was found (5) . Recently, it has been shown that flavonoids as constituents in a staple food, the African millet, are the cause of goiter and associated disorders (6) . To study the interactions of flavonoids with the iodine-thyroid hormone system, a model was chosen in the form of synthetic flavonoids. These flavonoids were developed by means of molecular drug design (1, 2, 4) . The synthetic flavonoids 3-methyl-4Ј,6-dihydroxy 3Ј,5Ј-dibromo-flavone (EMD 21388) and 3-methyl-4Ј,6-dihydroxy 3Ј,5Ј-diiodo-flavone (EMD 49209), both T 4 analogs, are potent inhibitors of the binding of T 4 to transthyretin (TTR), but not to other plasma proteins (1, 2, 7, 8) . These specific TTR competitors are useful tools to study distribution and kinetics of T 4 , as the synthetic flavonoids redistribute endogenous T 4 without the need to add exogenous (pharmacological) T 4 .
EMD 21388 in vitro inhibits 5Ј-deiodinase type I in rat liver microsomes (9) . In vivo studies with long term treatment of rats with EMD 21388 iv (20 mol/kg BW⅐day) showed that this synthetic flavonoid interferes with thyroid hormone secretion, turnover, and metabolism in several tissues in different ways (10 -13) . From the double isotope equilibrium study (10) , it was clear that in all tissues investigated T 4 concentrations decreased. In those tissues that express the 5Ј-iodothyronine deiodinase isoforms, liver, pituitary, testis, thymus, brown adipose tissue, brain, cerebellum, and hypothalamus, the amounts of T 3 locally produced from T 4 were decreased. The ratio of [ 125 I]T 3 /[ 125 I]T 4 was unchanged. It was not known whether these effects of EMD 21388 were due to inhibition of deiodinase isoforms or to a shortage of the amount of substrate, T 4 . As there were tissue-specific changes that differed from the effects expected from work in vitro, especially regarding the activity of the different 5Ј-deiodinase isoforms, it appeared important to assess whether the flavonoid enters into all organs and, if so, whether it does so similarly in all tissues.
To investigate this phenomenon we studied the distribution of EMD 49209, a congener of EMD 21388 in which bromide is replaced by iodide substituents on the phenolic ring. These iodide atoms were radiolabeled by an exchange labeling reaction with 125 I. We used this [ 125 I]radioactive flavonoid together with [
131 I]T 4 to address the question of the changes in the different T 4 distribution pools in the intact animal during long term treatment with the flavonoid. We compared their tissue distributions for up to 6 h after a bolus injection in rats pretreated with EMD 21388 iv for 14 days and in rats receiving the vehicle without EMD 21388 pretreatment.
Materials and Methods Animals
The experiments were approved by the local committee on animal care. Two groups of female Wistar rats (CPB/WU, Iffa Credo, Brussels, Belgium), about 180 g BW, were used. The rats were individually housed at 22 C, with alternating 14-h light and 10-h dark periods. They were fed the American Institute of Nutrition Diet (14) . Potassium iodide was added to the drinking water (10 mg/liter). One group (Exp B; n ϭ 7) was given EMD 21388 twice a day iv via a cannula that was inserted into the right jugular vein and extended to the right atrium (20 mol/kg BW⅐day) for 14 days. EMD 21388 (42.6 mg) was dissolved in 100 l sodium hydroxide (0.18 m), and saline was added directly to obtain 10 ml; the other group (Exp A; n ϭ 7) received the vehicle without EMD 21388 (10) . [ 131 I]T 4 was prepared freshly in our laboratory (15) . The purity of the radioactivity was assessed by HPLC just before use.
Preparation of radiolabeled compounds
125 I or percent 131 I was less than 0.1%, and no other labeled metabolites could be detected.
Experiments
On day 14 the rats received a bolus iv injection of 400 l 125 I]EMD 49209 is metabolized, plasma and tissues were extracted and subjected to HPLC chromatography following the same extraction procedure and HPLC protocol as those used for the separation of iodothyronines (16 4 were determined. The percent doses in tissues were corrected for trapped plasma (17) . The intestines of the rats were divided into five segments: three equal lengths of small intestine, cecum, and colon; feces and urine were collected, and for all of these fractions, the percent doses of 125 I and 131 I were determined. In total, 30 different organs were dissected and processed. For the sake of clarity, only those organs that contributed substantially to the changes in the distribution of the radioactivity are shown, the other organs are taken together and are shown as "rest." The percent doses in total blood, muscle, fat, skeleton, and skin were calculated according to the relative contribution to body weight (18) . The total contents of radioactivity in the intestinal segments and feces were also calculated.
After decay of the 131 I initially present in the plasma samples, the concentrations of T 4 and T 3 were assessed by rat RIA, using 131 I-labeled T 4 and T 3 , respectively, as tracers (19) . Free T 4 levels were measured by ultrafiltration using Microcon 10 (Amicon, Danvers, MA) filters and freshly labeled [
131 I]T 4 (20) . Plasma TSH was measured by the specific RIA developed for the rat by the NIDDK (NIH, Bethesda, MD). RP-2 was used as a standard.
Results
Both groups of rats had a normal increase in body weight. No toxic effects of EMD 21388 were observed (Exp B). Plasma T 4 and T 3 decreased in the EMD 21388-treated rats by approximately 55% and 28%, respectively. Although the percentage of free T 4 was higher, free T 4 concentrations were the same because of the lowered total plasma T 4 levels. Plasma TSH levels did not change (Table 1) . (Table 2A) . In many tissues, such as brain, cerebellum, hypothalamus, and medulla, the percent dose of 125 I radioactivity is very low, ranging from 0.0001-0.070% of the dose (Table 3) . After HPLC analysis, this activity appears to be iodide. (Table 2B ). In the intestines, about 22% was found after 6 h (Table 2B) (Fig. 1A) . EMD 21388 treatment resulted in an increase in the excretion of [ 125 I]EMD 49209 into the intestines as well as into the urine (Table 2C) . At the first time point (0.25 h), 38% of the [ 125 I]EMD 49209 was already present in the intestines, mainly in the first part of the jejunum (Fig. 2, I (Fig. 1B) . After 15 min, the uptake of T 4 by liver was very high (Table 2D) . After 6 h, a large part of the T 4 was still present in the liver and the various organs; the total excretion was 40% (intestines, 24%; urine, 16%). After pretreatment with EMD 21388, [ 131 I]T 4 distribution did not change markedly; there was less T 4 in the blood and more in the organs, and only a slight increase in excretion (Table 2D) 
Discussion
The T 4 plasma disappearance and tissue distribution results for Exp A are in accordance with the data obtained by our group in earlier studies, in which T 4 metabolism was measured under several experimental conditions and other experimental set-ups, such as the double isotope equilibrium technique (10, 13, 15, 16) .
The two flavonoids used in this study were developed by molecular drug design, directed toward the inhibition of the hepatic 5Ј-iodothyronine deiodinase. Both fulfill the criteria necessary for the optimal inhibitory potency (4). The only difference between these flavonoids is the two bromide atoms (EMD 21388) vs. the two iodide atoms (EMD 49209) in the 3Ј-and 5Ј-positions. This makes it possible that EMD 49209 can be deiodinated by deiodinases; debromination of EMD 21388 is less likely. That deiodination occurs can be seen from the free 125 I excreted in urine. This influences the kinetic behavior, which means that the disappearance rate of EMD 49209 is faster than that of EMD 21388; in the vehicletreated rats, it is about 10% (Exp A), and in EMD 21388-pretreated rats, it is about 20% (Exp B).
From our study it is clear that the synthetic flavonoid, [ 125 I]EMD 49209, disappears very quickly from plasma and enters tissues. However, the percent dose of the flavonoid in the organs is never high and decreases with time. It can be concluded from the rapid uptake of both compounds by the liver that this organ functions as an essential part of the fast pool. However, there is a discrepancy between T 4 and the flavonoid. T 4 content as a percentage of the dose in the liver is much higher than that of the flavonoid (with a high excretion into the intestinal lumen). This means that in liver, many binding sites exist for T 4 , but not for the flavonoid.
It appears that EMD 49209 does not bind to intracellular T 4 binding sites; there is a rapid transfer from plasma via the liver into the intestines. Also, EMD 21388 does not bind to nuclear thyroid hormone receptor (Bernal, J., personal com- (8, 21) . This also can explain the differences in the behavior of [
125 I]EMD 49209 between vehicle-treated and pretreated rats; in vehicletreated rats, the tracer amount of [
125 I]EMD 49209 will be totally bound to TTR, and its disappearance will be closely related not only to the binding to TTR, but also to the half-life of TTR. In the pretreated animals, the TTR is completely occupied by the EMD 21388, and the larger part of this flavonoid as well as [
125 I]EMD 49209 will exist in plasma in the free form. It is surprising that the plasma disappearance curves of EMD and T 4 are very similar, whereas their tissue distributions are essentially different.
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